Matinas BioPharma Holdings, Inc.
MTNB
$0.75
-$0.06-7.19%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 2.46M | 4.70M | 8.07M | 11.43M | 12.72M |
| Gross Profit | -2.46M | -4.70M | -8.07M | -11.43M | -12.72M |
| SG&A Expenses | 6.94M | 7.50M | 8.13M | 8.73M | 9.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.40M | 12.20M | 16.20M | 20.16M | 22.01M |
| Operating Income | -9.40M | -12.20M | -16.20M | -20.16M | -22.01M |
| Income Before Tax | -16.95M | -19.69M | -20.16M | -24.33M | -21.13M |
| Income Tax Expenses | -80.00K | -80.00K | -80.00K | -80.00K | -- |
| Earnings from Continuing Operations | -16.87 | -19.61 | -20.08 | -24.25 | -21.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.87M | -19.61M | -20.08M | -24.25M | -21.13M |
| EBIT | -9.40M | -12.20M | -16.20M | -20.16M | -22.01M |
| EBITDA | -9.28M | -11.99M | -15.91M | -19.79M | -21.63M |
| EPS Basic | -3.41 | -3.86 | -3.98 | -4.99 | -4.56 |
| Normalized Basic EPS | -1.15 | -1.50 | -1.99 | -2.59 | -2.85 |
| EPS Diluted | -3.41 | -3.86 | -3.98 | -4.99 | -4.56 |
| Normalized Diluted EPS | -1.15 | -1.50 | -1.99 | -2.59 | -2.85 |
| Average Basic Shares Outstanding | 20.70M | 20.30M | 20.20M | 19.46M | 18.72M |
| Average Diluted Shares Outstanding | 20.70M | 20.30M | 20.20M | 19.46M | 18.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |